{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:25:09Z","timestamp":1787505909199,"version":"build-2736575974"},"reference-count":52,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2025,11,23]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Differentiating type 1 myocardial infarctions (T1MI) from type 2 myocardial infarctions (T2MI) can be challenging based on clinical variables alone. This review aimed to explore the utility of novel and traditional biomarkers to discriminate between these entities and potentially provide additional prognostic information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of observational studies and randomised controlled trials that examined the discriminatory or prognostic roles of either traditional cardiac biomarkers (troponin, creatine kinase or b-type natriuretic peptide) or non-traditional biomarkers. Data sources included PubMed, SCOPUS, Web of Science, EMBASE and clinicaltrials.gov and were last searched on 15 November 2024. The diagnostic accuracy of biomarkers and prognostic utility of identified biomarkers are narratively reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>31 studies with 16\u2009111 individuals with a T2MI were included. Most studies (97%) demonstrated moderate or severe risk of bias. Of studies that examined traditional cardiac biomarkers (n=13), the ability to discriminate between T2MI and T1MI ranged from an area under the curve (AUC) of 0.61\u20130.71. Studies that added traditional cardiac biomarkers to clinical variables (n=4) demonstrated a diagnostic accuracy AUC 0.71\u20130.82. Studies exploring non-traditional biomarkers, metabolic and proteomic profiles (n=14) demonstrated a wide range of diagnostic accuracy (AUC 0.50\u20130.77). Traditional cardiac biomarkers inconsistently demonstrated a correlation with subsequent cardiovascular events. The prognostic utility of non-traditional biomarkers was infrequently assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The role of biomarkers, metabolic and proteomic profiles in the diagnosis and prognostication of T2MI remains unclear. Higher quality studies and refining the classification of T2MI may improve this further.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42023418095.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2025-003867","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:40:21Z","timestamp":1767775221000},"page":"e003867","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Utility of biomarkers in patients with a type 2 myocardial infarction: a systematic review"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-4786","authenticated-orcid":false,"given":"Pishoy","family":"Gouda","sequence":"first","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehzeen","family":"Lalani","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Newby","sequence":"additional","affiliation":[{"name":"Duke University Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schuyler","family":"Jones","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"2026010700401689000_13.1.e003867.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000617"},{"key":"2026010700401689000_13.1.e003867.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.02.018"},{"key":"2026010700401689000_13.1.e003867.3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/eurheartj\/ehae803","article-title":"Type 2 myocardial infarction: challenges in diagnosis and treatment","volume":"46","author":"Chapman","year":"2025","journal-title":"Eur Heart J"},{"key":"2026010700401689000_13.1.e003867.4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.20162","article-title":"Assessment of Oxygen Supply-Demand Imbalance and Outcomes Among Patients With Type 2 Myocardial Infarction: A Secondary Analysis of the High-STEACS Cluster Randomized Clinical Trial","volume":"5","author":"Bularga","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026010700401689000_13.1.e003867.5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2459\/JCM.0000000000000504","article-title":"Type 2 myocardial infarction: incidence, presentation, treatment and outcome in routine clinical practice","volume":"18","author":"Radovanovic","year":"2017","journal-title":"J Cardiovasc Med"},{"key":"2026010700401689000_13.1.e003867.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-34312-7","article-title":"Management and outcome trends in type 2 myocardial infarction: an investigation from the SWEDEHEART registry","volume":"13","author":"Eggers","year":"2023","journal-title":"Sci Rep"},{"key":"2026010700401689000_13.1.e003867.7","doi-asserted-by":"publisher","DOI":"10.1111\/acem.13033"},{"key":"2026010700401689000_13.1.e003867.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.05.049"},{"key":"2026010700401689000_13.1.e003867.9","doi-asserted-by":"publisher","DOI":"10.1177\/2048872614538411"},{"key":"2026010700401689000_13.1.e003867.10","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-312409"},{"key":"2026010700401689000_13.1.e003867.11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jamacardio.2019.0716","article-title":"Misclassification of Myocardial Injury as Myocardial Infarction: Implications for Assessing Outcomes in Value-Based Programs","volume":"4","author":"McCarthy","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026010700401689000_13.1.e003867.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.023052"},{"key":"2026010700401689000_13.1.e003867.13","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306093"},{"key":"2026010700401689000_13.1.e003867.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.05.026"},{"key":"2026010700401689000_13.1.e003867.15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031806"},{"key":"2026010700401689000_13.1.e003867.16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamacardio.2022.0043","article-title":"Characteristics and Outcomes of Type 2 Myocardial Infarction","volume":"7","author":"Coscia","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026010700401689000_13.1.e003867.17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/eurheartj\/ehab581","article-title":"Risk factors for type 1 and type 2 myocardial infarction","volume":"43","author":"Wereski","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010700401689000_13.1.e003867.18","doi-asserted-by":"crossref","unstructured":"Sterne JA , Hern\u00e1n MA , Reeves BC , et al . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;i4919. doi:10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"2026010700401689000_13.1.e003867.19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1515\/cclm-2017-0609","article-title":"No additional value of conventional and high-sensitivity cardiac troponin over clinical scoring systems in the differential diagnosis of type 1 vs. type 2 myocardial infarction","volume":"56","author":"Consuegra-S\u00e1nchez","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"2026010700401689000_13.1.e003867.20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.15441\/ceem.19.049","article-title":"Differential diagnostic factors of type 1 and type 2 myocardial infarction in patients with elevated cardiac troponin levels","volume":"7","author":"Seo","year":"2020","journal-title":"Clin Exp Emerg Med"},{"key":"2026010700401689000_13.1.e003867.21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.amjmed.2020.02.024","article-title":"A Comparison of Biomarker Rise in Type 1 and Type 2 Myocardial Infarction","volume":"133","author":"Pandey","year":"2020","journal-title":"Am J Med"},{"key":"2026010700401689000_13.1.e003867.22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054302"},{"key":"2026010700401689000_13.1.e003867.23","article-title":"Clinical and prognostic implications of high-sensitivity cardiac troponin T concentrations in type 2 non-ST elevation myocardial infarction","volume":"39","author":"Eggers","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026010700401689000_13.1.e003867.24","first-page":"40997263","article-title":"N-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide-to-Troponin - Ratios for Differentiating Type 1 From Type 2 Myocardial Infarction: A HIGH-US Substudy","volume":"24","author":"Memon","year":"2025","journal-title":"Crit Pathw Cardiol"},{"key":"2026010700401689000_13.1.e003867.25","first-page":"62","article-title":"Direct comparison of high-sensitivity cardiac troponin T and I in the early differentiation of type 1 vs. type 2 myocardial infarction","volume":"11","author":"Nestelberger","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026010700401689000_13.1.e003867.26","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.ajem.2018.06.073","article-title":"Differentiating type 1 and 2 acute myocardial infarctions using the N-terminal pro B-type natriuretic peptide\/cardiac troponin T ratio","volume":"36","author":"Nowak","year":"2018","journal-title":"Am J Emerg Med"},{"key":"2026010700401689000_13.1.e003867.27","doi-asserted-by":"crossref","unstructured":"Ma J , Bian S , Li A , et al . . CIA 2024;Volume 19:589\u201397. 10.2147\/CIA.S438541","DOI":"10.2147\/CIA.S438541"},{"key":"2026010700401689000_13.1.e003867.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx457"},{"key":"2026010700401689000_13.1.e003867.29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061264","article-title":"External Validation and Extension of a Clinical Score for the Discrimination of Type 2 Myocardial Infarction","volume":"10","author":"Nestelberger","year":"2021","journal-title":"J Clin Med"},{"key":"2026010700401689000_13.1.e003867.30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jacc.2022.10.025","article-title":"Improving Risk Stratification for Patients With Type 2 Myocardial Infarction","volume":"81","author":"Taggart","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010700401689000_13.1.e003867.31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjmed.2018.10.022","article-title":"Risk Estimation in Type 2 Myocardial Infarction and Myocardial Injury: The TARRACO Risk Score","volume":"132","author":"Cediel","year":"2019","journal-title":"Am J Med"},{"key":"2026010700401689000_13.1.e003867.32","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1161\/CIRCULATIONAHA.120.046682","article-title":"Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction","volume":"142","author":"Horiuchi","year":"2020","journal-title":"Circulation"},{"key":"2026010700401689000_13.1.e003867.33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MCA.0000000000000593","article-title":"The association between uric acid levels and different clinical manifestations of coronary artery disease","volume":"29","author":"Larsen","year":"2018","journal-title":"Coron Artery Dis"},{"key":"2026010700401689000_13.1.e003867.34","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACC.2021.06.027"},{"key":"2026010700401689000_13.1.e003867.35","article-title":"Serial measurements of protein and microRNA biomarkers to specify myocardial infarction subtypes","volume":"1","author":"Schulte","year":"2022","journal-title":"J Mol Cell Cardiol Plus"},{"key":"2026010700401689000_13.1.e003867.36","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1021\/acs.jproteome.7b00235","article-title":"Quantitation of 87 Proteins by nLC-MRM\/MS in Human Plasma: Workflow for Large-Scale Analysis of Biobank Samples","volume":"16","author":"Rezeli","year":"2017","journal-title":"J Proteome Res"},{"key":"2026010700401689000_13.1.e003867.37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijcard.2020.01.043","article-title":"Myeloid-related protein 8\/14 and high-sensitivity cardiac troponin I to differentiate type 2 myocardial infarction","volume":"304","author":"Bormann","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026010700401689000_13.1.e003867.38","doi-asserted-by":"crossref","first-page":"117745","DOI":"10.1016\/j.cca.2023.117745","article-title":"Pseudo-targeted metabolic profile differences between emergency patients with type 1 and type 2 myocardial infarction diagnosed by optical coherence tomography","volume":"554","author":"Wang","year":"2024","journal-title":"Clin Chim Acta"},{"key":"2026010700401689000_13.1.e003867.39","doi-asserted-by":"crossref","first-page":"131879","DOI":"10.1016\/j.ijcard.2024.131879","article-title":"Copeptin for the differentiation of type 1 versus type 2 myocardial infarction or myocardial injury","volume":"403","author":"Kassem","year":"2024","journal-title":"Int J Cardiol"},{"key":"2026010700401689000_13.1.e003867.40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.14336\/AD.2019.0405","article-title":"Type 2 Myocardial Infarction: A Geriatric Population-based Model of Pathogenesis","volume":"11","author":"Putot","year":"2020","journal-title":"Aging Dis"},{"key":"2026010700401689000_13.1.e003867.41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122100","article-title":"Type 1 or Type 2 Myocardial Infarction in Patients with a History of Coronary Artery Disease: Data from the Emergency Department","volume":"8","author":"Putot","year":"2019","journal-title":"J Clin Med"},{"key":"2026010700401689000_13.1.e003867.42","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2147\/CIA.S416372","article-title":"Prediction of Outcomes Through Cystatin C and cTnI in Elderly Type 2 Myocardial Infarction Patients","volume":"18","author":"Ma","year":"2023","journal-title":"Clin Interv Aging"},{"key":"2026010700401689000_13.1.e003867.43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajem.2025.08.019","article-title":"Differentiating Type 1 and Type 2 myocardial infarction using a machine learning algorithm and biomarkers","volume":"98","author":"Snavely","year":"2025","journal-title":"Am J Emerg Med"},{"key":"2026010700401689000_13.1.e003867.44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jamacardio.2021.0669","article-title":"Cardiovascular Biomarkers in the Early Discrimination of Type 2 Myocardial Infarction","volume":"6","author":"Nestelberger","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026010700401689000_13.1.e003867.45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3143\/geriatrics.42.229","article-title":"The assessment of the reliability and the validity of the EOQOL questionnaire of osteoporotics-QOL assessment of elderly osteoporotics by EOQOL-","volume":"42","author":"Horiuchi","year":"2005","journal-title":"Jpn j geriat"},{"key":"2026010700401689000_13.1.e003867.46","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.hrtlng.2024.12.008","article-title":"Biomarker profiles that differentiate type-1 and type 2 myocardial infarction","volume":"70","author":"Mele","year":"2025","journal-title":"Heart & Lung"},{"key":"2026010700401689000_13.1.e003867.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.08.1038"},{"key":"2026010700401689000_13.1.e003867.48","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw054"},{"key":"2026010700401689000_13.1.e003867.49","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"2026010700401689000_13.1.e003867.50","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-074820","article-title":"Evaluation of clinical prediction models (part 2): how to undertake an external validation study","volume":"384","author":"Riley","year":"2024","journal-title":"BMJ"},{"key":"2026010700401689000_13.1.e003867.51","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082440","article-title":"Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide","volume":"390","author":"Lopez-Ayala","year":"2025","journal-title":"BMJ"},{"key":"2026010700401689000_13.1.e003867.52","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2025-003867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:40:29Z","timestamp":1767775229000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2025-003867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,6]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/openhrt-2025-003867"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2025-003867","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}